Toward Preventing Transplant Rejection with Immunologically Matched Stem Cells

Donor stem cell–derived retinal epithelial cells whose immune proteins correspond to those of a recipient are tolerated following transplant into monkeys’ eyes, according to a report published today (September 15) in Stem Cell Reports. In an accompanying paper, the team also reports that such immune-matched retinal cells derived from humans prevent immune responses in cultured human lymphocytes.

Read at The Scientist

Cancer researchers claim ‘extraordinary results’ using T-cell therapy

This is unprecedented’ says researcher after more than half of terminally ill blood cancer patients experienced complete remission in early clinical trials

A scanning electron micrograph of a human T lymphocyte (also called a T-cell).
A scanning electron micrograph of a human T-cell. ‘T-cells are a living drug, and in particular they have the potential to persist in our body for our whole lives,’ said researcher Chiara Bonini. Photograph: Alamy

Scientists are claiming “extraordinary” success with engineering immune cells to target a specific type of blood cancer in their first clinical trials.

Among several dozen patients who would typically have only had months to live, early experimental trials that used the immune system’s T-cells to target cancers had “extraordinary results”.

In one study, 94% of participants with acute lymphoblastic leukaemia (ALL) saw symptoms vanish completely. Patients with other blood cancers had response rates greater than 80%, and more than half experienced complete remission.

Link to full article at The Guardian